Sam Brusco, Associate Editor09.07.22
Ortho Regenerative Technologies, a clinical-stage orthobiologics firm developing novel soft tissue repair regenerative technologies, has changed its name to ChitogenX Inc.
According to the company, the name better reflects the company’s growing clinical and commercial opportunities, mission, values, and core competencies. ChitogenX’s shares are expected to start trading under the ticker “CSE: CHGX” on or around September 12.
"We evaluated our company name in light of the vast potential clinical and commercial applications for our proprietary technology platform, and it was obvious that these applications were much broader than just the orthopedic field the previous corporate name was inferring to," CEO Philippe Deschamps told the press. "We opted for a new company name that better represented our identity and expanded possibilities. ChitogenX achieves both."
According to the company, the name better reflects the company’s growing clinical and commercial opportunities, mission, values, and core competencies. ChitogenX’s shares are expected to start trading under the ticker “CSE: CHGX” on or around September 12.
"We evaluated our company name in light of the vast potential clinical and commercial applications for our proprietary technology platform, and it was obvious that these applications were much broader than just the orthopedic field the previous corporate name was inferring to," CEO Philippe Deschamps told the press. "We opted for a new company name that better represented our identity and expanded possibilities. ChitogenX achieves both."